S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Home
Investing
Stocks
UK
LSE
Roche Holding Ag (0QQ6)
Roche Holding Ag (0QQ6) News

0QQ6

Roche (0QQ6)

Roche Holding Ag

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:LSE:0QQ6

1

Date	Time	Source	Headline	Symbol	Company
05/27/2024	12:00AM	UK Regulatory	Wechsel in der erweiterten Konzernleitung von Roche	LSE:0QQ6	Roche Holding Ag
05/27/2024	12:00AM	UK Regulatory	Changes to the Roche Enlarged Corporate Executive Committee	LSE:0QQ6	Roche Holding Ag
05/22/2024	12:00AM	UK Regulatory	Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk	LSE:0QQ6	Roche Holding Ag
05/21/2024	12:00AM	UK Regulatory	FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation	LSE:0QQ6	Roche Holding Ag
05/16/2024	12:00AM	UK Regulatory	[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity	LSE:0QQ6	Roche Holding Ag
05/15/2024	12:00AM	UK Regulatory	Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer	LSE:0QQ6	Roche Holding Ag
04/24/2024	12:00AM	UK Regulatory	[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19	LSE:0QQ6	Roche Holding Ag
04/24/2024	12:00AM	UK Regulatory	[Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne COVID-19-Produkte	LSE:0QQ6	Roche Holding Ag
04/19/2024	12:00AM	UK Regulatory	FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer	LSE:0QQ6	Roche Holding Ag
04/17/2024	1:00AM	UK Regulatory	Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS	LSE:0QQ6	Roche Holding Ag
04/15/2024	12:00AM	UK Regulatory	[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study	LSE:0QQ6	Roche Holding Ag
04/11/2024	12:00AM	UK Regulatory	Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis	LSE:0QQ6	Roche Holding Ag
03/26/2024	11:45AM	UK Regulatory	Roche receives FDA approval for the first molecular test to screen for malaria in blood donors	LSE:0QQ6	Roche Holding Ag
03/12/2024	7:30AM	UK Regulatory	Roche Generalversammlung 2024	LSE:0QQ6	Roche Holding Ag
03/12/2024	7:30AM	UK Regulatory	Assemblée générale 2024 de Roche	LSE:0QQ6	Roche Holding Ag
03/12/2024	7:30AM	UK Regulatory	Roche Annual General Meeting 2024	LSE:0QQ6	Roche Holding Ag
03/05/2024	6:30AM	UK Regulatory	Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care	LSE:0QQ6	Roche Holding Ag
02/25/2024	1:00PM	UK Regulatory	New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies	LSE:0QQ6	Roche Holding Ag
02/16/2024	10:24AM	UK Regulatory	FDA approves Xolair as first and only medicine for children and adults with one or more food allergies	LSE:0QQ6	Roche Holding Ag
02/01/2024	12:03AM	UK Regulatory	New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)	LSE:0QQ6	Roche Holding Ag
02/01/2024	12:00AM	UK Regulatory	[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche übertrifft Guidance für 2023 und erzielt trotz stark rückläufigem COVID-19-Umsatz Verkaufswachstum von 1% (CER)	LSE:0QQ6	Roche Holding Ag
02/01/2024	12:00AM	UK Regulatory	[Annonce événementielle au sens de l’art. 53 RC] Roche dépasse les projections et affiche une croissance des ventes de 1 % (TCC) en 2023, malgré un net recul des ventes lié au COVID-19	LSE:0QQ6	Roche Holding Ag
02/01/2024	12:00AM	UK Regulatory	[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline	LSE:0QQ6	Roche Holding Ag
10/23/2023	6:18AM	IH Market News	Monday’s Wall Street Highlights: Philips, Chevron, Textainer, Okta, Roivant, and more	LSE:0QQ6	Roche Holding Ag

Showing the most relevant articles for your search:LSE:0QQ6

1

State Street Global Advi...

Proteome Sciences

Graniteshares 3x Long Nv...

Cantor Fitzgerald Sustai...

Euronext Core Europe 30 ...

Mandarin Oriental (PK)

Euronext G Societe Gener...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions